1. Home
  2. ALT vs INVZ Comparison

ALT vs INVZ Comparison

Compare ALT & INVZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • INVZ
  • Stock Information
  • Founded
  • ALT 1997
  • INVZ 2016
  • Country
  • ALT United States
  • INVZ Israel
  • Employees
  • ALT N/A
  • INVZ N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • INVZ Auto Parts:O.E.M.
  • Sector
  • ALT Health Care
  • INVZ Consumer Discretionary
  • Exchange
  • ALT Nasdaq
  • INVZ Nasdaq
  • Market Cap
  • ALT 327.4M
  • INVZ 369.4M
  • IPO Year
  • ALT N/A
  • INVZ N/A
  • Fundamental
  • Price
  • ALT $3.87
  • INVZ $1.97
  • Analyst Decision
  • ALT Strong Buy
  • INVZ Buy
  • Analyst Count
  • ALT 6
  • INVZ 4
  • Target Price
  • ALT $17.40
  • INVZ $2.77
  • AVG Volume (30 Days)
  • ALT 2.5M
  • INVZ 6.4M
  • Earning Date
  • ALT 11-11-2025
  • INVZ 11-12-2025
  • Dividend Yield
  • ALT N/A
  • INVZ N/A
  • EPS Growth
  • ALT N/A
  • INVZ N/A
  • EPS
  • ALT N/A
  • INVZ N/A
  • Revenue
  • ALT $20,000.00
  • INVZ $37,684,000.00
  • Revenue This Year
  • ALT N/A
  • INVZ $153.22
  • Revenue Next Year
  • ALT $761,880.20
  • INVZ $91.44
  • P/E Ratio
  • ALT N/A
  • INVZ N/A
  • Revenue Growth
  • ALT N/A
  • INVZ 17.32
  • 52 Week Low
  • ALT $2.90
  • INVZ $0.45
  • 52 Week High
  • ALT $11.16
  • INVZ $3.14
  • Technical
  • Relative Strength Index (RSI)
  • ALT 55.49
  • INVZ 61.56
  • Support Level
  • ALT $3.56
  • INVZ $1.67
  • Resistance Level
  • ALT $3.72
  • INVZ $1.95
  • Average True Range (ATR)
  • ALT 0.18
  • INVZ 0.14
  • MACD
  • ALT 0.03
  • INVZ 0.02
  • Stochastic Oscillator
  • ALT 51.15
  • INVZ 98.00

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About INVZ Innoviz Technologies Ltd. Ordinary shares

Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.

Share on Social Networks: